April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Safety Profile of Anti-VEGF Agents on Retinal Pigment Epithelium Cells: In Vitro Cell Viability
Author Affiliations & Notes
  • Simon R Bababeygy
    Ophthalmology, Gavin Herbert Eye Institute, UC Irvine, Irvine, CA
  • Deepika Malik
    Ophthalmology, Gavin Herbert Eye Institute, UC Irvine, Irvine, CA
  • Javier Caceres del Carpio
    Ophthalmology, Gavin Herbert Eye Institute, UC Irvine, Irvine, CA
  • David S Boyer
    Ophthalmology, Retina-vitreous Associates Medical Group, Los Angeles, CA
  • Cristina M Kenney
    Ophthalmology, Gavin Herbert Eye Institute, UC Irvine, Irvine, CA
  • Baruch Kuppermann
    Ophthalmology, Gavin Herbert Eye Institute, UC Irvine, Irvine, CA
  • Footnotes
    Commercial Relationships Simon Bababeygy, None; Deepika Malik, None; Javier Caceres del Carpio, None; David Boyer, None; Cristina Kenney, None; Baruch Kuppermann, Alcon (C), Alimera (C), Allegro (C), Allergan (C), Genentech (C), Glaukos (C), GSK (C), Neurotech (C), Novagali (C), Novartis (C), Ophthotech (C), Pfizer (C), Regeneron (C), Santen (C), SecondSight (C), Teva (C), ThromboGenics (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 596. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Simon R Bababeygy, Deepika Malik, Javier Caceres del Carpio, David S Boyer, Cristina M Kenney, Baruch Kuppermann; Safety Profile of Anti-VEGF Agents on Retinal Pigment Epithelium Cells: In Vitro Cell Viability. Invest. Ophthalmol. Vis. Sci. 2014;55(13):596.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

While the advent of anti-VEGF drugs ranibizumab, bevacizumab, and aflibercept have revolutionized the treatment of wet AMD, differences in molecular structure of these drugs may have variable effects on enzymatic activity and metabolic processes in retinal cells, and may cause mild occult toxicity despite their significant benefit. This study was designed to compare the safety profiles of anti-VEGF drugs ranibizumab, bevacizumab, aflibercept, and ziv-aflibercept on retinal pigment epithelium cells in culture by assessing cell viability post drug exposure.

 
Methods
 

Human retinal pigment epithelium cells (ARPE-19) were exposed for 24 hours to one of four anti-VEGF drugs at 1/2X, 1X, 2X or 10X clinical doses. Cell viability using the trypan blue dye exclusion assay was performed to evaluate the amount of overall cell death post drug exposure for each drug.

 
Results
 

Ranibizumab was found to be safe at all doses of treatment including the highest dose, 10X the clinical dose. There was no statistically significant difference between control and all ranibizumab doses tested from 1/2X to 10X clinical dose. Cell viability of ARPE-19 cells treated with 10X dose of bevacizumab, aflibercept and ziv-aflibercept showed a statistically significant decrease to 82.38 + 1.5% (p=0.0002), 82.62 + 1.7% (p=0.0001) and 77.25 + 2.1% (p<0.0001), respectively compared to control (normalized to 100%). There were no statistically significant differences on ARPE-19 cells between at 1/2X, 1X and 2X anti-VEGF treated cells compared to control/untreated cells.

 
Conclusions
 

At clinical equivalent doses, none of the four anti-VEGF drugs tested exhibited significant decreases in cell viability on ARPE-19 cells in culture. However, at supranormal doses 10X the clinical dose, only ranibizumab showed no significant decrease in RPE cell viability. At 10X the clinical dose, bevacizumab, aflibercept, and ziv-aflibercept all showed significant decreases in RPE cell viability. This study suggests that ranibizumab may have the broadest safety profile of all four studied anti-VEGF drugs tested on RPE cells in culture.

 
 
Cell Viability Percentage
 
Cell Viability Percentage
 
Keywords: 412 age-related macular degeneration • 688 retina • 748 vascular endothelial growth factor  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×